Investigational trials of anticancer drugs: establishing safeguards for experimentation.
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields



Publication Date Range:


Document Data


Document Type:






Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page


Investigational trials of anticancer drugs: establishing safeguards for experimentation.

Filetype[PDF-1.14 MB]

  • English

  • Details:

    • Alternative Title:
      Public Health Rep
    • Description:
      The National Cancer Institute since 1955 has been charged with responsibility for discovering new anti-cancer agents and bringing them to clinical trial. These activities are carried out by NCI's Developmental Therapeutics Program, which has established systems for discovery, experimental testing, bulk synthesis, formulation, and toxicological testing of candidate drugs, and by the Cancer Therapy Evaluation Program, which conducts initial trials to establish safe doses of new agents and to determine their utility in treating specific forms of cancer. These clinical trials are conducted both at NCI in Bethesda, Md., and at selected cancer centers throughout the United States. This paper describes the safeguards that NCI has built into the clinical trials system in the past decade-safeguards that ensure the safety of patients and the accuracy of data collected and at the same time allow efficient testing of each promising new agent in the fight against cancer. Recent improvements in cancer survival leave little doubt that patients are indeed benefiting from extensive efforts to discover and develop new drugs for cancer treatment.
    • Pubmed ID:
    • Pubmed Central ID:
    • Document Type:
    • Place as Subject:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    Related Documents

    You May Also Like

    Checkout today's featured content at